Medicaments for the treatment of anxiety

Claim 2

Use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT "M" receptors for the manufacture of a medicament for the treatment of anxiety, excluding tetrahydrocarbazolone derivatives of the general formula (I) wherein R a represents a hydrogen atom or a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-(C 1-4 )alkyl, C 3-6 alkenyl, C 3-10 alkynyl, phenyl or phenyl-(C 1-3 )alkyl group, and one of the groups represented by R b , R c and R d is a hydrogen atom or a C 1-6 alkyl, C 3-7 cycloalkyl, C 2-6 alkenyl or phenyl-(C 1-3 )alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C 1-6 alkyl group; and physiologically acceptable salts and solvates thereof.

Claim 3

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is an azabicyclo derivative or a benzoic acid derivative.

Claim 4

Use according to claim 2 wherein the azabicyclo derivative contains a bridged piperidyl group such as a tropyl, pseudotropyl, homotropyl or quinuclidinyl group.

Claim 5

Use according to claim 2 wherein the benzoic acid derivative is a benzoate or benzamide derivative.

Claim 6

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is a compound of formula (II) wherein R 1 and R 2 independently represent hydrogen, halogen, C 1-4 alkoxy, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 ) alkylamino, mercapto or C 1-4 alkylthio; R 3 represents hydrogen, C 1-4 alkyl, C 3-5 alkenyl, aryl or aralkyl; , R 4 represents hydrogen, C 1-7 alkyl, C 3-5 alkenyl or aralkyl; n is 2 or 3; the free valence is attached to either fused ring and the azabicyclic ring is in either the exo or endo configuration or an acid addition salt or quaternary ammonium salt thereof.

Claim 7

Use according to claim 5 wherein R 1 and R 2 independently represent hydrogen, halogen or C 1-4 alkyl, R 3 is hydrogen or C 1-4 alkyl, R 4 is hydrogen, C 1-7 alkyl or aralkyl, the carbonyl group is attached to the 3- position of the indole ring and the azabicyclic ring is in the endo configuration.

Claim 8

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is a compound of formula (III) wherein R 5 represents C 1-4 alkyl, C 1-4 alkoxy or halogen; and R 6 and R 7 independently represent hydrogen, C 1-4 alkyl, C 1-4 alkoxy or halogen; provided that (a) when the azabicyclo ring is in the endo configuration and R 7 is hydrogen then R 6 is hydrogen or R 5 and R 6 are both alkyl, and (b) when the azabicyclic ring is in the exo configuration R 5 is a C 1-4 alkyl group; or a pharmaceutically acceptable salt thereof.

Claim 9

Use according to claim 7 wherein the azabicyclo ring is in the endo configuration.

Claim 10

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is a compound of formula (IV) wherein R 8 represents C 1-4 alkyl; R 9 represents C 1-4 alkyl, C 1-4 alkoxy or halogen; and p is zero or an integer from 1 to 5; provided that when p is 2 the groups represented by Rg can be the same or different and when p is 3, 4 or 5 the groups represented by R 9 are the same; or a pharmaceutically acceptable salt thereof.

Claim 11

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is a compound of formula (V) wherein R 10 represents a C 1-6 alkoxy or amino N-substituted by one or two groups selected from C 1-6 alkyl or C 3-8 cycloalkyl or optionally N-substituted by C 4-5 polymethylene; one of R 11 , R 12 and R13 is hydrogen and the other two are independently selected from hydrogen, chloro, bromo, trifluoromethyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 alkyl and amino; one of R 14 and R 15 represents hydrogen, C 1-6 alkyl, phenyl, or phenylC 1-3 alkyl, which phenyl moieties may be substituted by C 1-6 alkyl, C 1-6 alkoxy, CF 3 or halogen, and the other of R 14 and R 15 is hydrogen or C 1-6 alkyl; q is zero or an integer from 1 to 4; r is zero, or an integer from 1 to 3; and s is zero, 1 or 2.

Claim 12

Use according to claim 10 wherein R1 0 is methoxy, R 11 is hydrogen, R 12 is 4-amino, R 13 is 5-chloro (relative to the benzamide group), R 14 and R 15 independently represent hydrogen or C 1-6 alkyl; q is zero, r is 1 or 2 and s is zero, 1 or 2.

Claim 13

Use according to claim 1 wherein the compound which acts as an antagonist of 5-HT at 5-HT "M" receptors is selected from: 1αH,3α,5αH-tropan-3-yl-3,5-dichlorobenzoate; 1αH,3α,5αH-tropan-3-yl-3,5-dimethylbenzoate; (3α-tropanyl)-1H-indole-3-carboxylic acid ester; and (±)-endo-4-amino-5-chloro-2-methoxy-N-(1-azabicyclo-[3.3.3]-non-4-yl)benzamide.